Novo Nordisk to Acquire AstraZeneca’s Spin-off Corvidia for ~$2.1B

 Novo Nordisk to Acquire AstraZeneca’s Spin-off Corvidia for ~$2.1B

Novo Nordisk to Acquire AstraZeneca’s Spin-off Corvidia for ~$2.1B

Shots:

  • Novo Nordisk to acquire in all-cash transaction, making a total deal value ~$2.1B which included $725M as upfront and a remaining as regulatory and sales milestones
  • The acquisition of Corvidia Therapeutics along with its lead candidate, ziltivekimab allow the Novo Nordisk to expand its footprints across cardiometabolic diseases
  • Ziltivekimab is a fully human mAb targeting IL-6, is being evaluated P-IIb RESCUE study to reduce the risk of MACE in CKD patients with ASCVD and inflammation. AstraZeneca had acquired Corvidia for $443M in 2013 and spun out it in 2015

Click here to read full press release/ article | Ref: Novo Nordisk | Image: Corvidia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post